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Abstract Tau is a neuronal microtubule-associated protein
whose function is modulated by phosphorylation. GSK-3L is a
tau kinase. GSK-3L is part of the wingless signalling pathway
and stimulation by wingless is predicted to down-regulate GSK-
3L activity. In Drosophila imaginal disc cells, overexpression of
dishevelled, a component of the wingless pathway, mimics the
wingless signal. We have therefore studied the effect that
overexpression of the murine dishevelled-1 protein has on GSK-
3L-mediated phosphorylation of tau in transfected CHO cells.
We find that co-transfection with dishevelled-1 is inhibitory to
GSK-3L-mediated tau phosphorylation. Tau is hyperphospho-
rylated in Alzheimer's disease and the possible relevance of these
findings to Alzheimer's disease pathogenesis are discussed.
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1. Introduction
Tau is a neuronal microtubule-associated protein that is
localised in axons (see [1] for review). Tau promotes micro-
tubule assembly in vitro [2] and is probably involved in the
formation and maintenance of axons [3,4].
The function of tau is in£uenced by its phosphorylation
status; phosphorylated tau has a reduced a¤nity for micro-
tubules and is less potent at promoting microtubule assembly
in vitro [5^8]. Likewise, phosphorylation of tau in tau trans-
fected cells can also reduce its ability to bind to microtubules
and this can in£uence cellular microtubule organisation [9^
12].
Glycogen synthase kinase-3 (GSK-3K and GSK-3L) are ser-
ine/threonine kinases that phosphorylate tau both in vitro and
in cultured cells [11^21]. GSK-3L is the mammalian homo-
logue of the Drosophila zeste white 3 gene (zw3 or shaggy)
product, a component of the wingless signal transduction
pathway ([22] and see [23^25]). Wingless, a member of the
Wnt growth factor family, plays an important role in early
patterning of the Drosophila embryo (see [24,25]). Recently, a
member of the Drosophila frizzled gene family (Dfz2) has been
shown to function as a wingless receptor [26]. Genetic studies
have shown that dishevelled, a cytoplasmic protein down-
stream of Dfz-2 is essential for reception of the wingless signal
(see [27]). Wingless signalling via dishevelled results in the
inactivation of Zw3 and this leads to increased stability of
armadillo (arm) (see [23^25,28] for reviews). Components of
the wingless signalling pathway are conserved in mammals
with L-catenin being the mammalian homologue of armdillo.
The molecular mechanism(s) by which stimulation of the
Wnt pathway leads to inactivation of GSK-3L are not fully
understood although recent studies suggest that it may involve
protein kinase C isoforms [29]. However, genetic studies place
dishevelled upstream of, and closest to, GSK-3L. Interestingly,
elevation of dishevelled protein levels by transfection into
Drosophila imaginal disc cell lines mimics the wingless signal
by increasing the levels of arm [30]. Overexpression of dishev-
elled therefore appears to be an experimental route that en-
ables downstream activation of the wingless pathway.Since
stimulation of the wingless pathway appears to down-regulate
GSK-3L activity and since overexpression of dishevelled by
transfection can mimic such stimulation, we have examined
whether overexpression of the mouse dishevelled-1 (Dvl-1)
protein can in£uence GSK-3L-mediated phosphorylation of
tau in transfected mammalian cells.
2. Materials and methods
2.1. Expression plasmids
For expression of tau, a tau cDNA comprising the smallest human
tau isoform containing no amino-terminal inserts and three carboxy-
terminal repeat regions cloned into pSG5 (Stratagene) as previously
described was used [11]. GSK-3L was expressed using a GSK-3L
cDNA cloned into pMT2 as described [16]. To express mouse dishev-
elled-1 (Dvl-1), a cDNA encoding mouse Dvl-1 [31] was cloned as an
EcoRI to XhoI fragment into the EcoRI and SalI sites of pCIneo
(Promega). As a control, the chloramphenicol acetyltransferase
(CAT) gene was also cloned into pCIneo by removing the CAT
gene from pMSG-CAT (Pharmacia) as a SalI fragment and cloning
into the SalI site of pCIneo.
2.2. Cell culture, transfection and Western blotting
Chinese hamster ovary (CHO) cells were grown in K-MEM con-
taining 10% v/v foetal bovine serum plus supplements and transfected
using a Promega Profection kit. For Western blotting, transfected
cells were washed with PBS and harvested by scraping into sodium-
dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE)
sample bu¡er and heating in a boiling water bath. Proteins were
separated on either 8% gels or on 4^15% gradient gels, transferred
to nitrocellulose and probed with primary antibodies. Tau antibodies
were TP70, a phosphorylation-independent rabbit polyclonal antibody
[16] and the phosphorylation-dependent mouse monoclonal antibodies
AT8, 8D8 and AT180. AT8 detects tau phosphorylated on ser
202
and
thr
205
, 8D8 detects tau phosphorylated on ser
396
and AT180 detects
tau phosphorylated on thr
231
[13,32^34]. AT antibodies were obtained
from Innogenetics Ghent, Belgium. To study Dvl-1 expression, a rab-
bit polyclonal antibody raised against a GST-mouse Dvl-1 fusion
protein was used. L-catenin was detected with a rabbit polyclonal L-
catenin antibody. Blots were developed using the Enhanced Chemilu-
minescence (ECL) detection system (Amersham).
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3. Results
To investigate how experimental manipulation of Dvl-1 ex-
pression might in£uence phosphorylation of tau, we studied
tau from CHO cells transiently transfected with tau, tau+Dvl-
1, tau+GSK-3L and tau+Dvl-1+GSK-3L. Since one aim of
these experiments was to compare tau phosphorylation in
tau+GSK-3L co-transfected cells with tau+GSK-3L+Dvl-1
co-transfected cells, we controlled for the di¡erent numbers
of plasmids transfected by including in those transfections
involving only one or two plasmids, either empty vector or
vector expressing CAT. All transfections therefore received
the same numbers and amounts of plasmids; tau only trans-
fected cells contained tau+2 CAT (or 2 empty vector);
tau+Dvl-1 transfected cells contained tau+Dvl-1+1 CAT (or
1 empty vector); tau+GSK-3L transfected cells contained
tau+GSK-3L+1 CAT (or one empty vector). All transfections
were performed at least three times and produced identical
results. No di¡erences were observed between transfections
involving the empty vector or transfections in which the
CAT plasmid was used as a control.
To study Dvl-1 expression in CHO cells, we utilised a Dvl-1
antibody to probe Western blots of Dvl-1 transfected and
non- or mock/CAT-transfected cells. This antibody reacted
strongly with several species that migrated as a broad band
between approximately 78 and 90 kDa in Dvl-1 transfected
cells (Fig. 1); (extended exposure of the blots revealed some
weaker reactivity in non-transfected cells with species in the
70^90 kDa range (not shown)). The predicted molecular
weight of Dvl-1 is 75 kDa [31]. Drosophila dishevelled is phos-
phorylated in response to the wingless signal and overexpres-
sion of dishevelled also induces its phosphorylation [30]. Thus,
the broad smear of reactivity that we observe in the Dvl-1
transfected CHO cells might possibly be due to di¡erential
phosphorylation. Whatever the reason, the intense labelling
that we observe with the Dvl-1 antibody in Dvl-1 transfected
but not non-transfected cells, clearly demonstrates that Dvl-1
is being over-expressed after transfection of the plasmid.
We next studied tau phosphorylation in the transfected
CHO cells. Western blot analyses of tau only transfected cells
with the phosphorylation-independent antibody TP70 re-
vealed that the tau migrated as a doublet (Fig. 2 track 2).
However, co-transfection of tau with GSK-3L induced a
marked reduction in electrophoretic mobility of a proportion
of the tau so as to generate new slower migrating species (Fig.
2 tracks 4 and 5). These results are consistent with previous
observations of tau and tau+GSK-3L transfected cells
[11,12,16^18]. Tau from cells co-transfected with tau+Dvl-1
migrated in a similar fashion to cells transfected with tau
alone (Fig. 2 track 3). However, tau from cells transfected
with tau+GSK-3L+Dvl-1 migrated in a di¡erent pattern to
cells transfected with tau+GSK-3L ; instead of the marked
reduction in electrophoretic mobility of the tau induced by
GSK-3L, only a partial reduction in electrophoretic mobility
was detected (Fig. 1 tracks 6 and 7). These results were seen in
cells in which either empty vector or CAT vector was used to
control for co-transfection of the additional Dvl-1 plasmid.
Since the decrease in electrophoretic mobility of the tau
induced by GSK-3L is due to phosphorylation of the tau
[11,12,16^18], the above results suggest that co-transfection
of Dvl-1 somehow inhibits phosphorylation of tau. To explore
this possibility further, we utilised three phosphorylation-de-
pendent tau antibodies (whose epitopes are all generated, at
least in part, by GSK-3L) to study the phosphorylation status
of tau in the various transfections. Consistent with previous
observations of tau and tau+GSK-3L transfected CHO cells
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Fig. 2. Western blot with phosphorylation-independent tau antibody
TP70 of cells transfected with tau, Dvl-1 and GSK-3L. Track 1,
mock-transfected cells; track 2, cells transfected with tau+2CAT;
track 3, cells transfected with tau+Dvl-1+1CAT; track 4, cells trans-
fected with tau+GSK-3L+1CAT; track 5, repeat of track 4 but dif-
ferent transfection; track 6, cells transfected with tau+GSK-3L+Dvl-
1; track 7, repeat of track 6 but di¡erent transfection.
Fig. 3. Western blot of cells transfected with tau, GSK-3L and Dvl-
1 with phosphorylation-dependent tau antibodies AT8 (a), 8D8 (b)
and AT180 (c). Track 1, mock-transfected cells; track 2, cells trans-
fected with tau+2 CAT; track 3, cells transfected with tau+Dvl-
1+1CAT; track 4, cells transfected with tau+GSK-3L+1CAT; track
5, cells transfected with tau+GSK-3L+Dvl-1.
Fig. 1. Western blot with a polyclonal Dvl-1 antibody of mock
transfected cells (track 1) or cells transfected with the Dvl-1 plasmid
(track 2). Molecular masses of markers are shown on the left.
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[11,17], tau transfected alone into cells failed to react, or re-
acted weakly with antibodies AT8, 8D8 and AT180 (Fig. 3a^c
tracks 2) but co-transfection of tau with GSK-3L induced
strong reactivity with a tau species that corresponded to the
slower migrating species detected by antibody TP70 (Fig. 2
track 4). This was shown by cutting blots in half and probing
one half with TP70 and the other with the phosphorylation-
dependent antibodies. Co-transfection of tau with Dvl-1 pro-
duced labelling patterns that were highly similar to those seen
following transfection of tau alone (Fig. 3 tracks 2 and 3).
However, co-transfection of Dvl-1 with tau and GSK-3L ei-
ther abolished, or markedly reduced the GSK-3L-induced re-
activity with AT8, 8D8 and AT180 (Fig. 3 track 5). Thus co-
transfection of Dvl-1 appears to inhibit GSK-3L-mediated
phosphorylation of tau.
To determine whether this inhibitory in£uence on GSK-3L-
mediated phosphorylation of tau was restricted solely to the
transfected tau and to determine whether Dvl-1 overexpres-
sion could also inhibit the e¡ect that GSK-3L has on an
endogenous cellular protein, we studied the levels of L-catenin
in the various transfections. CHO cells are highly transfect-
able and our immuno£uorescence studies revealed that a high
proportion of the cells in the transient transfections (more
than 50%) express transfected proteins. Since most cells ex-
press the transfected proteins, we therefore reasoned that it
was feasible to search for e¡ects of GSK-3L/Dvl-1 on L-cat-
enin in these transient transfected cells. GSK-3L activity
down-regulates the levels of cytoplasmic L-catenin/armadillo
and stimulation of the wingless pathway is predicted to inhibit
this process [30,35^37]. Overexpression of GSK-3L led to a
decrease in the levels of L-catenin in the CHO cells but this
e¡ect was inhibited by co-expression of Dvl-1 with GSK-3L
(Fig. 4). Thus Dvl-1 also appears to inhibit the e¡ect that
GSK-3L has on the levels of endogenous L-catenin.
4. Discussion
In this report, we have investigated the e¡ect that overex-
pression of the mouse Dvl-1 protein, a component of the Wnt
signalling pathway, has on GSK-3L-mediated phosphoryla-
tion of tau in transfected CHO cells. Stimulation of the wing-
less pathway is predicted to result in down-regulation of
GSK-3L activity (see [23^25,28] for reviews) and indeed, re-
cent studies have shown that stimulation of 10T1/2 cells with
wingless does indeed inhibit GSK-3 activity [29]. Overexpres-
sion of dishevelled in Drosophila imaginal disc cells mimics
stimulation of the wingless pathway as assayed by accumula-
tion of arm and hyperphosphorylation of dishevelled [30]
although whether such overexpression alters GSK-3L activity
has not been shown. Our ¢nding that overexpression of Dvl-1
inhibits GSK-3L-mediated phosphorylation of tau is therefore
consistent with these earlier reports which show that overex-
pression of dishevelled results in increased arm stability, prob-
ably by inhibiting Zw3 (GSK-3L).
Dvl-1 is widely expressed in adult tissues of the mouse in-
cluding the brain, the major site of tau expression [31]. The
ability of tau to in£uence cellular microtubule organisation
appears to be modulated by phosphorylation and in particular
by phosphorylation via GSK-3L [11,12]. Recent results gener-
ated by some of us have demonstrated that Wnt increases
neurite spreading and branching in primary neuronal cultures
[38] although whether such cytoskeletal rearrangements are
due to changes in tau phosphorylation via Dvl-1 and GSK-
3L are not established.
Tau is hyperphosphorylated in the paired helical ¢laments
(PHF) found in the brains of patients with Alzheimer's disease
and many of the sites that are phosphorylated in PHF-tau are
targets for GSK-3L [11^18]. Mutations in the presenilin genes
are the cause of most of the early onset, familial forms of
Alzheimer's disease [39,40] and genetic studies in C. elegans
have shown that a worm presenilin homologue is genetically
linked to lin-12, a C. elegans Notch gene [41]. Recently, di-
shevelled has been shown to interact with Notch so as to
connect the wingless and Notch signalling pathways [42].
Although only tentative at present, a genetic link therefore
appears to exist between the presenilin family of proteins
and dishevelled. In this context, our observations that dishev-
elled can in£uence tau phosphorylation suggests a possible
route by which alterations in presenilin function might lead
to Alzheimer-type changes in tau phosphorylation.
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